The FDA has limited the use of COVID-19 antibody therapies developed by Eli Lilly and Regeneron, on the back of data suggesting they have are "highly unlikely" to be effective against the n
AstraZeneca's antibody cocktail for COVID-19, now called Evusheld, has become the first drug in the class to be authorised for prevention of infection by the US FDA.
The UK medicines regulator has approved GlaxoSmithKline and Vir Biotech's antibody for COVID-19, Xevudy, which has been shown to be effective against the new Omicron strain of SARS-CoV-2 in
The US has made a sizeable order for GlaxoSmithKline and Vir Biotechnology's antibody-based COVID-19 treatment sotrovimab said to be worth approximately $1 billion.
The EMA's human medicines committee has recommended approval of Roche's Ronapreve and Celltrion's Regkirona for use in COVID-19, the first antibody-based therapies for coronavirus to be bac
A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.